Rusfertide

Phase 3Peptide

Protagonist Therapeutics

Rusfertide is one of 38 small molecule programs targeting Polycythemia Vera. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Polycythemia VeraActive, not recruiting

Polycythemia VeraPhase 3

Active, not recruiting

Competition

Competitive Landscape

45 competitors in Polycythemia Vera

#DrugCompanyPhaseTrials

Droxia

TTheravia

Approved

5 2

BESREMI

PPharmaEssentia

Approved

3 3

Jakafi

Incyte

Phase 3

10 4

Ojjaara

GGlaxo Dba Glaxosmithkline

Trisenox

Zolinza

CCidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)

PEG-Intron

Duvyzat

3 9

Best Available Therapy

Novartis

Phase 3

2 10

Bayer Aspirin

Bayer

Phase 2

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q2 2027

Phase 3Active, not recruiting

Polycythemia Vera

NCT05210790

Clinical

Trials by Indication[1]

Polycythemia Vera1 trial

A Phase 3 Study of Rusfertide in Patients With Polycythemia Vera

Active, not recruiting· Protagonist Therapeutics logo

Protagonist Therapeutics·Phase 3·NCT05210790·293 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Rusfertide. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Rusfertide compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Rusfertide. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Protagonist Therapeutics company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Peptide[2]
Highest Phase: Phase 3[1]
Company: Protagonist Therapeutics

Rusfertide

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q2 2027

Trials by Indication[1]

Polycythemia Vera1 trial

References

Drug Info

Quick Facts

Related News